Scott Reid on Questions Passed as Orders for Returns

With regard to preparation and response to COVID-19: (a) which provinces and territories have signed the Multi-Lateral Information Sharing Agreement (MLISA), and on what dates were each of their signatures provided; (b) which provinces and territories have declined to sign the MLISA, on what dates were each of their refusals provided, and what objections did each raise to signing; (c) which provinces and territories have withdrawn from the MLISA since signing it, and on what dates were their withdrawals effective; (d) is the MLISA currently in force, and, if not, why not; (e) which provinces and territories have signed the Federal/Provincial/Territorial Memorandum of Understanding on the Sharing of Information During a Public Health Emergency (Sharing MOU), and on what dates were each of their signatures provided; (f) which provinces and territories have declined to sign the Sharing MOU, and on what dates were their refusals provided; (g) which provinces and territories have withdrawn from the Sharing MOU since signing it, and on what dates were their withdrawals effective; (h) is the Sharing MOU currently in force, and, if not, why not; (i) which provinces and territories are using the Public Health Agency of Canada’s (PHAC) COVID-19 Case Report Form; (j) what percentage of known COVID-19 cases in Canada were reported to the PHAC using its COVID-19 Case Report Form versus other means; (k) when the PHAC’s COVID-19 Case Report Form instructs to "report cases electronically using secure methods or fax”, which secure methods does the PHAC utilize, and which methods are used, broken down by provinces and territories; (l) what percentage of known COVID-19 cases reported to the PHAC were reported using fax or paper; (m) how many full-time equivalents does the PHAC employ or have on contract to enter COVID-19 case reports received by fax or paper into electronic means; (n) what is the shortest, longest, and average delay that the PHAC experiences when a COVID-19 case report is received by fax or paper before it is entered into electronic means; (o) what is the reason for the discrepancy between the total number of cases of COVID-19 reported by the Government of Canada on its “Coronavirus disease (COVID-19): Outbreak update” website, and the smaller number of cases with specific epidemiological data on the website entitled “Detailed confirmed cases of coronavirus disease”; (p) what are the factors that contribute to the delay between the reporting of the “episode date” of a COVID-19 case and the “date [the] case was last updated”, with reference to the data referred to in (o); (q) which provinces and territories have objected to the public disclosure of their detailed COVID-19 case data, as on the “Detailed confirmed cases of coronavirus disease” website, and for each province and territory, what are the details or summary of their objection; (r) why, in developing its COVID-19 Case Report Form, did the PHAC choose not to collect the ethnicity or race of individuals, as done in other jurisdictions; (s) why has the government never used its powers under section 15 of the Public Health Agency of Canada Act to better collect and analyze COVID-19 case data held by the provinces; (t) why has the PHAC not yet published an epidemiological model of COVID-19 that includes a scientifically detailed public disclosure of the modelling methodology, computer code, and input parameters; (u) what are the reasons that the PHAC does not publish a daily COVID-19 model that includes up-to-date estimates of the effective reproductive number (R), such as that produced by Norway, in its model of May 8, 2020; (v) what is the value, duration, objectives and deliverables of the contract issued by the Government of Canada to Blue Dot for the modelling of COVID-19, announced by the Prime Minister on March 23, 2020; (w) which other individuals or companies has the Government of Canada contracted for the modelling of COVID-19, and, for each contract, what is the (i) value, (ii) duration, (iii) objectives, (iv) deliverables; (x) do any of the contracts for COVID-19 limit the freedom of the contractors to disclose the information, methodology, or findings of their models as confidential, and, if so, which contracts are so affected, and what are the terms of the confidentiality; (y) what is the total amount of federal spending on the Panorama public health and vaccination data system since its launch; (z) which provinces and territories utilize Panorama’s disease outbreak management and communicable disease case management modules for reporting COVID-19 information to the federal government; (aa) to what extent does the federal government have access to COVID-19 outbreak and case data contained within the Panorama system and what are the reasons for the lack of access to data, if any; (bb) what steps has the federal government taken to ensure that, when data exists, it will have access to COVID-19 vaccination data contained within the Panorama system; (cc) to what extent does the Panorama system meet the data collection and reporting goals of the federal government’s report entitled “Learning from SARS – Renewal of Public Health in Canada”; and (dd) has an audit of the Panorama system been completed and, if so, what are the details of the audit’s findings, including when it was done, by whom it was conducted, and the standards by which it was measured?